Dr. Aparna Parikh speaks at the Choosing Wisely Meeting & BMC Conclave about the significant challenges in detecting recurrent disease in cancer patients, particularly using circulating tumour DNA (ctDNA) as a biomarker. She notes that around 30% of patients with major solid tumours experience recurrence despite curative treatment. While current surveillance methods have limited sensitivity, ctDNA can detect residual disease at very low levels. Serial testing further enhances detection rates, though adjuvant chemotherapy shows only modest effects. Dr. Parikh also discusses the future of ctDNA testing and the challenges faced in MRD trials, especially regarding testing infrastructure.